Bleeding Disorder Testing Market Analysis

Bleeding Disorder Testing Market Analysis

Based on product, the market is segmented as reagents & consumables and instruments. Reagents & consumables dominated the market in 2022 accounting for more than 58% of the total revenue share. This high revenue share is majorly attributed to the availability of precise diagnostic kits, numerous product launches, and frequent technological advancements in the diagnostic technology. For instance, in March 2020, Siemens Healthineers launched its new Sysmex CS-2500 System with PS-2500 Automated Sample Preparation Module. This modality is a fully automated hemostasis analyzer that provides high throughput testing and improved efficiency. Such product launches offer improved functionality and more reliable diagnostics. Hence, the above-mentioned factors are projected to significantly fuel the bleeding disorder testing market statistics.
 

Based on indication, the bleeding disorder testing market is segmented as hemophilia A, hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, and others. The hemophilia A segment held the largest revenue share in 2022 and is expected to significantly expand at a 7.5% CAGR from 2023-2032. This significant segmental share is due to the higher prevalence of hemophilia A, significant products that cater to the condition, and surging disease awareness among the population.
 

Based on end-use, the bleeding disorder testing market is segmented as hospitals & clinics, diagnostic centers, and others. The diagnostic laboratories segment accounted for over USD 38 million in 2022 and is projected to expand at a notable pace throughout the forecast period. This considerable segment growth is owing to the availability of specialized and efficient diagnoses with rising awareness related to severe bleeding diseases. The expansion of diagnostic laboratory chains with developing infrastructure providing clinical testing services for a wide range of diseases is set to proliferate the market revenue. These diagnostic laboratories are aimed towards the expansion of their reach across the nation to provide diagnostic services including bleeding disorder testing.
 

Additionally, the use of advanced screening mechanisms at diagnostic laboratories drives patient preference. Thus, considering the above-mentioned factors, the increasing testing at diagnostic laboratories will drive the market demand during the estimation timeframe.
 

U.S. dominated the North America bleeding disorder testing market with a dominant revenue share in 2022 and is anticipated to reach more than USD 54 million by 2032. This high revenue surge is majorly attributed to multiple variables such as the facilitative initiatives, high disease prevalence, new product launches along with the presence of established manufacturers. The increasing awareness associated with technologically novel products and the surging target population pool is also contributing to the market revenue growth.